The Antibody Drug Conjugates (ADC) Market report points out national and global business prospects and competitive conditions for antibody drug conjugates (ADC). Market size estimation and forecasts were given based on a detailed research methodology tailored to the conditions of the demand for antibody drug conjugates (ADC). The antibody drug conjugates (ADC) market has been segmented indication (lymphoma, breast cancer, brain tumor, lung cancer, ovarian cancer, others), by target (antibody-protein toxin conjugates, antibody-chelated radionuclide conjugates, antibody-small-molecule drug conjugates, antibody-enzyme conjugates). Historical background for the demand of antibody drug conjugates (ADC) has been studied according to organic and inorganic innovations in order to provide accurate estimates of the market size. Primary factors influencing the growth of the demand antibody drug conjugates (ADC) have also been established with potential gravity. Major regions covered in the study include North America, Europe, Asia Pacific, Middle East & Africa, and South America.
- Breast Cancer
- Brain Tumor
- Lung Cancer
- Ovarian Cancer
- Antibody-Protein Toxin Conjugates
- Antibody-Chelated Radionuclide Conjugates
- Antibody-Small-Molecule Drug Conjugates
- Antibody-Enzyme Conjugates
North America Antibody drug conjugates (ADC) Market
- North America, by Country
- North America, by Indication
- North America, by Target
Europe Antibody drug conjugates (ADC) Market
- Europe, by Country
- The Netherlands
- Rest of Europe
- Europe, by Indication
- Europe, by Target
Asia Pacific Antibody drug conjugates (ADC) Market
- Asia Pacific, by Country
- South Korea
- Rest of Asia Pacific
- Asia Pacific, by Indication
- Asia Pacific, by Target
Middle East & Africa Antibody drug conjugates (ADC) Market
- Middle East & Africa, by Country
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
- Middle East & Africa, by Indication
- Middle East & Africa, by Target
South America Antibody drug conjugates (ADC) Market
- South America, by Country
- Rest of South America
- South America, by Indication
- South America, by Target
Major Companies: Seattle Genetics, Inc., Genentech Inc., Pfizer Inc., Novartis AG, F. Hoffmann-LA Roche Ltd., Bristol -Myers Squibb, Merck & Co., Inc. Immunomedics Inc.
Years Covered in the Study:
Historic Year: 2017-2018
Base Year: 2019
Estimated Year: 2020
Forecast Year: 2028
Objectives of this report:
- To estimate market size for antibody drug conjugates (ADC) market on regional and global basis.
- To identify major segments in antibody drug conjugates (ADC) market and evaluate their market shares and demand.
- To provide a competitive scenario for the antibody drug conjugates (ADC) market with major developments observed by key companies in the historic years.
- To evaluate key factors governing the dynamics of antibody drug conjugates (ADC) market with their potential gravity during the forecast period.
Reasons to Buy This Report:
- Provides niche insights for decision about every possible segment helping in strategic decision making process.
- Market size estimation of the antibody drug conjugates (ADC) market on a regional and global basis.
- A unique research design for market size estimation and forecast.
- Identification of major companies operating in the market with related developments
- Exhaustive scope to cover all the possible segments helping every stakeholder in the antibody drug conjugates (ADC)
This study is customized to meet your specific requirements:
- By Segment
- By Sub-segment
- By Region/Country
- Product Specific Competitive Analysis
For more information, contact: [email protected]